DBV Technologies S.A.
NASDAQ: DBVT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Daniel Tassé
- Employees
- 106
- Headquarters
- Montrouge, France
- IPO year
- 2014
- Market cap
- $373.2M
- Website
- https://www.dbv-technologies.com
Loading DBVT…
Loading profile data…Frequently asked questions about DBVT
What does DBV Technologies S.A. (DBVT) do?
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents,...
Where does DBVT trade?
DBV Technologies S.A. (DBVT) trades on the NASDAQ Global Select.
What sector is DBVT in?
DBV Technologies S.A. (DBVT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of DBV Technologies S.A.?
Daniel Tassé is the chief executive officer of DBV Technologies S.A. (DBVT).
Where is DBV Technologies S.A. headquartered?
DBV Technologies S.A. is headquartered in France.
Does DBVT pay a dividend?
DBV Technologies S.A. (DBVT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DBVT go public?
DBV Technologies S.A. (DBVT) completed its initial public offering in 2014.
Is DBVT an ADR?
Yes — DBVT is an American Depositary Receipt; its underlying shares trade on a non-US exchange. DBV Technologies S.A. reporting and dividends follow the underlying issuer.